Using Education to Improve Human Papillomavirus Vaccine Uptake among Adolescents by Collins, Kristina M.
Running head: HPV VACCINE EDUCATION  1 
 
 
  
  
  
  
  
 
 
 
 
 
 
 
 
  
  
  
  
  
Using Education to Improve Human Papillomavirus Vaccine Uptake among Adolescents  
Kristina M. Collins  
University of Missouri-Kansas City  
Approved May 2019 by the faculty of UMKC in partial fulfillment of the requirements for the 
degree of Doctor of Nursing Practice ©2019 
Kristina M. Collins 
All Rights Reserved 
 
  
  
  
  
  
 
 
HPV VACCINE EDUCATION 
 
2 
Abstract  
The human papillomavirus vaccine protects adolescents against the human papillomavirus and 
is recommended for all males and females starting at age 11. The human papillomavirus vaccine 
is an effective approach to reduce infections and associated cancers however, vaccination uptake 
continues to lag behind other vaccines common in adolescents. This evidence based proposal 
aimed to improve human papillomavirus vaccine uptake among adolescents using an education 
bundle. This project was a quasi-experimental, single group, prospective design which focused 
on ten adolescents age eleven through fourteen, who scheduled a well child check or sports 
physical in an urban pediatric clinic. An educational bundle was implemented prior to receiving 
the human papillomavirus vaccine to improve vaccine uptake. This outcome was evaluated by 
measuring vaccination uptake among adolescents who received the educational materials 
compared to baseline data from retrospective chart reviews. Results suggest that the use of the 
education bundle had a positive impact on HPV vaccine uptake with a 46.7 percent rate of 
acceptance among the pre-education group, n=16, compared to an 80 percent acceptance rate 
among the post-education group, n=10. When adolescents consistently accept the human 
papillomavirus vaccine, the overall prevalence and transmission of the virus are 
decreased and associated cancers can be prevented in the United States. Through the use 
of education, healthcare providers can improve the current human papillomavirus vaccine rates 
and reduce the prevalence of human papillomavirus infections and associated health 
complications among adolescents.  
Keywords: human papillomavirus, vaccine, education, adolescents, uptake, barriers  
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Using Education to Improve Human Papillomavirus Vaccine Uptake among Adolescents  
Human papillomavirus (HPV) is a group of more than 200 viruses that can lead to health 
problems such as sexually transmitted infections (STIs), genital warts, and certain types of 
cancer (Centers for Disease Control and Prevention (CDC), 2015). HPV is transmitted through 
intimate skin to skin contact and is currently the most common STI affecting nearly 80 million 
people in the United States (CDC, 2015). The HPV vaccine protects adolescents against cancers 
caused by specific strains of HPV, a large number of the HPV viruses, and boosts the overall 
immune system (CDC, 2015).  
HPV vaccination is recommended to prevent the virus and the associated complications 
(CDC, 2016). The HPV vaccine has been recommended for all males and females starting at age 
11 since 2006 (CDC, 2016). In 2016, the Advisory Committee on Immunization Practices 
(ACIP) updated their recommendation to include a two-dose vaccine series for all adolescents 
who initiated the series at age 11 through 14 (Meites, Kempe, & Markowitz, 2016). A three-dose 
series is still recommended for all adolescents who receive the first dose at age 15-26 (Meites, 
Kempe, & Markowitz, 2016). The HPV vaccine is an effective approach to reduce HPV 
infections as well as the rates of high-grade cervical lesions (Markowitz, Hariri, & Lin, 2013). 
However, HPV vaccination uptake continues to lag behind other vaccinations common in 
adolescents (Voelker, 2013).  
Significance of HPV 
It is estimated that 90 percent of sexually active females will be infected with HPV at 
some point in their life (CDC, 2014). The majority of HPV infections clear spontaneously, 
however for 20 percent of women and men, HPV will lead to genital warts, precancerous lesions, 
and certain cancers (Printz, 2015). The HPV infection plays a critical role in the development of 
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cancer and results in 33,000 cases of cancer annually in the United States (CDC, 2015; Printz, 
2015).   
The HPV vaccine provides protection against the HPV strains that are most likely to 
cause cervical cancer (Petrosky et al., 2015). Due to new recommendations, there is one vaccine 
approved for the protection against HPV in the United States; Gardisil 9 (Petrosky et al., 2015). 
The Gardisil 9 vaccine was approved in 2010 and provides protection against nine different HPV 
strains which are responsible for nearly 90% of all cervical cancer and genital warts (Petrosky et 
al., 2015; Van Damme et al., 2015).   
A 2010 survey showed that only 25% of 13 through 17-year-old females received one 
dose of the HPV vaccine and only 11% of females received all three doses of the vaccination 
(Dorrell, Stokley, & Yankey, 2012). Currently, Kansas and Missouri have some of the lowest 
reported HPV vaccine compliance in the country (Gutierrez, 2016). HPV related cancer 
incidence in Missouri is 8.3 per 100,000 cases, which is higher than the national average of 7.4 
(National Cancer Institute, 2015). These statistics become increasingly difficult when paired with 
state vaccination coverage. In Missouri only 38.5 percent of girls and 33.3 percent of boys have 
received and completed the HPV vaccine series (CDC, 2016). 
Diversity Considerations  
Kansas City, Missouri has a population of 458787, and 6.3 percent are adolescents age 10 
through 14 (U.S Census Bureau, 2010). The average household income is $47489 and the current 
poverty rate is 18.3 percent (U.S Census Bureau, 2010). About 59 percent of the population 
identify themselves as Caucasian and 30 percent identify as African American (U.S Census 
Bureau, 2010). However, exploring by the zip code where the clinic is located, 47 percent are 
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Caucasian and 45 percent are African American (U.S Census Bureau, 2010). Five percent of 
individuals are also Spanish-speaking so interpretive services are often utilized.   
The pediatric clinic for this project is accessible via private vehicle, public transportation, 
and outreach programs that assist individuals with additional transportation modes if necessary 
(J. Garney, personal communication, March 22, 2018). The current demographics of the 
adolescents that are cared for in this clinic are not available to the student investigator. The 
diverse demographics of Kansas City improve generalizability to a larger population.  
Problem Statement and Intended Improvement 
The problem statement for this evidence based project (EBP) is, In spite of multiple 
guidelines established by the American College of Obstetrics and Gynecology (ACOG), 
American Cancer Society (ACS), and the American Academy of Pediatrics (AAP) which 
promote the use of the HPV vaccine among adolescents, the immunization rate for HPV 
prevention is as low as 25% in some areas of the United States (ACOG, 2017; Saslow et al., 
2016; Committee on infectious Diseases, 2012). The purpose of this EBP project is to determine 
if the evidence-based use of an education bundle will increase the first dose of the HPV vaccine 
uptake in adolescents 11 through 14 years of age at SHS in Kansas City, Missouri.   
HPV is the most common STI in the United States, with strains linked to oropharyngeal, 
cervical, and other types of cancer (Osazuwa-Peters, 2013). The HPV vaccine is a safe and 
effective way to reduce HPV infections among adolescents (CDC, 2015). It is important for 
healthcare providers to acknowledge this gap in HPV vaccine uptake in order to implement 
effective practice change. According to the Journal of Cancer Education and the Journal of 
Health Psychology, simple interventions such as education regarding the HPV vaccine, change 
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of parental attitudes about the HPV vaccine in a positive way, increasing overall HPV 
vaccination uptake (Cox, 2010; Spleen, 2011). 
Facilitators and Barriers  
 The main facilitators of this project are the setting of the study, access to the vaccine and 
necessary supplies, and the current pediatric nurse practitioner at the clinic who has agreed to 
assist the student investigator with project implementation. Parents have reported safety 
concerns, lack of clinician recommendation, and low-levels of knowledge as factors involved in 
choosing not to vaccinate their children (Remes et al., 2012; Rhodes et al., 2017). These 
knowledge gaps can be easily addressed by healthcare providers through education and HPV-
specific written educational materials (see Appendix A).  
 Costs are minimal in this project and consist of paper and printer ink which facilitate this 
project. The author will not be compensated for her time during this project which will further 
decrease costs. The additional cost breakdown is provided in the budget and funds table (see 
Appendix B). Finally, there is a high potential for sustainability during the project. The education 
provided by the advanced practice registered nurse (APRN) will be very brief, written materials 
can be easily obtained from the CDC website, and this pediatric clinic is ideal because it 
routinely performs well child checks for adolescents age 11 through 14. There are also resources 
available if cost is an issue.  
Review of Evidence 
PICOTS  
The inquiry for this project is, In adolescent patients, age 11 through 14, does the use of 
an education bundle compared to patients who received no education increase the uptake of the 
Human papillomavirus (HPV) vaccine during a 3-month time frame in a primary care setting?  
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Search Strategies  
The University of Missouri-Kansas City (UMKC) Health Sciences Library was used to 
perform a literature search for relevant articles and evidence supporting the use of education to 
improve HPV vaccine uptake. This library includes key databases such as Cumulative Index of 
Nursing and Allied Health Literature (CINAHL), Index Medicus (MEDLINE), and PubMed. 
The National Guideline Clearinghouse (NGC) was also used to search for current evidence-based 
recommendations. Keywords that were used for this search include HPV, vaccine, education, 
uptake, rate, adolescent, barriers, and knowledge. A definition of terms has also been provided 
to clarify vocabularies (see Appendix C). 
Search results yielded 148 peer-reviewed studies. Inclusion and exclusion criteria for this 
search were based on the age of participants, publication date, setting of the study, and 
vaccination status. Studies for this project focused on adolescent males and females age 11 
through 18 and excluded results that discussed participants over the age of 26. All studies 
supporting this EBP project were published within the last 10 years, specifically focusing on 
interventions performed in a primary care setting.  
A total of 19 publications were collected to provide the evidence to support the inquiry 
and intervention (see Appendix D). Utilizing the Rating System for the Hierarchy of an 
Intervention Inquiry (see Appendix E), each study was given a specific level of evidence 
(Melnyk & Overholt, 2015, adapted). Of the 13 quantitative studies, seven studies were Level III 
and four studies were level II. The mixed method approach was also deemed a level III study. Of 
the two qualitative studies, one was a level V, and one was a Level VI. Lastly, all five clinical 
guidelines were classified as a level I on the hierarchy since they are the latest evidence-based 
practices relating to HPV vaccination.    
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Synthesis of Evidence by Sub-topics 
There are three topics relevant to the inquiry: HPV vaccine uptake, HPV vaccine 
education, and current clinical practice guidelines. The studies included six studies related to 
HPV vaccine uptake, which is the outcome that is being evaluated, and eight studies relevant to 
HPV vaccine education which is the intervention being implemented. Lastly, it is currently 
recommended that all adolescents ages 11 through 14 receive two doses of the HPV vaccine six 
to 12 months apart (CDC, 2016). In addition, five practice recommendations were identified that 
were relevant to current clinical practice guidelines. 
HPV Vaccine Uptake 
Adolescents report various influences in decision-making for receiving the HPV vaccine. 
In two quantitative studies, researchers utilized questionnaires in order to evaluate the effect of 
healthcare provider communication and vaccine awareness (Bhatta, & Phillips, 2014; Tung, 
Machalek & Garland, 2016). In the study by Bhatta and Phillips (2014), females and males less 
than 14 years of age receiving the HPV vaccine were significantly more likely to have a 
discussion with a parent or healthcare provider (OR=3.74; 95% CI: 2.30-6.06). Survey results 
from a study by Tung, Machalek and Garland (2016) indicated attitudes toward HPV infection 
may impact the success of the HPV vaccination program. In one quantitative study, researchers 
exclusively analyzed parental acceptance of the HPV vaccine before and after counseling 
sessions and came to similar conclusions (Mofunanya, 2011).  
It is essential for healthcare providers to understand both parental and adolescent 
preferences to significantly improve HPV vaccination uptake (Kessels, 2012; May et al., 2017). 
One qualitative study performed face-to-face interviews or telephone interviews with adolescents 
and their parents (n=20) in order to shed light on this concept (May et al., 2017). Seventy percent 
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reported that they had gained HPV knowledge from their physician, confirming that physician 
recommendation has a significant impact on HPV vaccination uptake. One systematic review 
examined additional factors that are associated with HPV vaccine uptake.  
Lastly, one randomized controlled trial (RCT) analyzed vaccine uptake specifically 
among college females age 18 through 26 (Patel, 2012). Results showed that at baseline 41% 
intended to initiate the HPV vaccine series however, overall HPV vaccine uptake was only 5.5 
percent. Children and teens account for 18% of all preventive visits, therefore healthcare 
providers play an essential role in the uptake of the HPV vaccine (CDC, 2016). This data stresses 
the importance of advocating for the initiation of the HPV vaccine series at every appointment. 
HPV Vaccine Education 
Education is an intervention that healthcare providers can offer to adolescents and their 
parents in order to improve knowledge and overall HPV vaccine uptake (Spleen, 2011). 
According to the Journal of Cancer Education and the Journal of Health Psychology, simple 
interventions such as education regarding the HPV vaccine change parental attitudes in a positive 
way, increasing overall HPV vaccine uptake (Cox, 2010; Spleen, 2011). Education delivery, 
audience, and knowledge will be evaluated in this evidence based topic. 
In one systematic review researchers focused on the audience to be educated (Fu, 
Bonhomme, & Spring, 2014). Results showed that there was a significant increase on intent to 
vaccinate among parents after receiving educational brochures (RR 95% CI 1.6-2.88), and 
adolescents who received CDC fact sheets report an 11% increase in vaccination uptake. Another 
quantitative study performed by Krawczyk (2012) explored the effect of specific types of 
education; comparing written and video intervention and their effect of vaccination intentions. 
Thirty-six percent of participants reported high intent to vaccinate, although both intervention 
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groups reported an increase in knowledge and intent neither intervention significantly improved 
vaccine uptake (Krawczyk, 2012). 
One quantitative study addressed tailoring education to an audience by implementing a 
multilingual and multicultural HPV educational DVD (Valdez et al., 2015). Participants attended 
an educational session and completed a questionnaire assessing their knowledge of HPV. Results 
showed that knowledge significantly increased (p<0.0001) regarding HPV and cervical cancer in 
the educational group compared to the control group. These results suggest that multicultural and 
multilingual education is beneficial in increasing HPV vaccine knowledge among a diverse 
population.  
A cross sectional approach was used to evaluate the predictors of adults’ knowledge and 
awareness of HPV, utilizing HPV vaccine rates (McBride & Singh, 2017). Knowledge was 
measured using the Health Information National Trends Survey (HINTS) survey. Sixty percent 
of women participants and 44% of men participants report having ever heard of HPV. A majority 
of the respondents also reported to not believe that the HPV vaccine is effective in preventing 
specific cancers; verifying that significant knowledge gaps exist (McBride & Singh, 2017). One 
quantitative study aimed to determine the most effective way to present HPV to improve HPV 
vaccination uptake among adolescents (Cox, 2011). Demographic characteristics, family history 
of cervical cancer, and perceptions of their daughter’s sexual activity were assessed in this study 
however none of these variables significantly correlated with intent to vaccinate (p<0.05).  
Another quantitative study also assessed knowledge and its effect on HPV vaccine uptake 
(Spleen et al., 2011). Adolescent caregivers attended an HPV educational session with an 
immediate follow-up questionnaire. Knowledge regarding HPV increased for all participants 
(p<0.0001) as well as intent to vaccinate (p=0.002). When followed up in one month 100% of 
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participants continued to state the education was helpful, and 44% of the caregivers reported 
initiating the vaccine series.  
Most educational sessions were performed in a primary care setting, but the author 
included one study that initiated education within schools (Rieter, Stubbs, & Panozzo, 2011). 
This quantitative study analyzed the effect of education on parents, healthcare staff, and school 
staff. Participants were asked to rate their knowledge level (p<0.001) and attend a 30-minute 
HPV-specific educational session. Following the educational session more than 90% of school-
staff and 97% of parents reported believing that HPV education is valuable within schools. 
 When providing HPV vaccine education, it is important to involve both adolescents and 
their parents to maximize intent to vaccinate (Fu, Bonhomme, & Spring, 2014). There is a clear 
correlation between education and knowledge, however current literature often lacks a further 
connection to HPV vaccine initiation and completion (Cox, 2011; McBride & Singh, 2017; 
Spleen, 2010).  Currently no one method of education has been significantly more effective in 
HPV vaccine uptake (Fu, Bonhomme & Spring, 2014; Krawczyk, 2012). Utilizing multicultural 
written materials along with education has also been effective in similar studies (Valdez et al., 
2015; Krawczyk, 2012).   
Clinical Guidelines 
The CDC, ACOG, ACS, and AAP all recommend that adolescents initiate the HPV 
vaccine series at age 11 (Gardner et al., 2016; Nikoyan & Fischer; Saslow et al., 2016). This age 
is now recommended because it is likely that this population is not yet exposed to the HPV virus 
(CDC, 2015). As of 2016, it is also recommended that teens between 11 and 14 only receive two 
vaccinations, instead of the previously recommended three-dose series (Gardner et al., 2016; 
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Nikoyan & Fischer; Saslow et al., 2016). This two-dose recommendation is also aimed to 
improve completion of the HPV vaccine series (Nikoyan & Fischer, 2016).  
Additional recommendations discuss presence of pre-cancers and routine cervical 
screenings (ACOG, 2017; Saslow et al, 2016). The HPV vaccine should be obtained regardless 
of a woman’s abnormal Pap tests or pre-cancers and it is highly recommended that all women 
over the age of 21 continue routine cervical cancer screenings in order to prevent and reduce the 
severity of HPV infections (ACOG, 2017; CDC, 2015; Saslow et al., 2016). One quantitative 
systematic review reviewed the effectiveness of the HPV vaccine over 10 years (Garland et al., 
2016). After six years of HPV vaccine availability HPV six, 11, 16, and 18 among women 
between 18 through 24 decreased by 76% after one dose of the HPV, and 86% after completion 
of the series (Garland et al., 2016). High-grade cervical cytological abnormalities also declined 
47% over five years of the vaccination program. These results reinforced current evidence, 
leading the CDC (2015) to recommend a broad three-dose HPV coverage among adolescents to 
advance global public health. 
In 2016, the CDC updated their recommendation to a simpler, two-dose vaccine series 
among adolescents nine through 14 (Nikoyan & Fischer, 2016). The ACOG (2017) focused their 
recommendations on girls and boys receiving their first dose of the HPV vaccine. This guideline 
states that all adolescents who initiate the HPV vaccine series between the ages of 11 through 14 
only need two doses of the vaccine, endorsing current CDC recommendations (Nikoyan & 
Fischer, 2016). This recommendation has changed recently due to evidence stating that HPV 
immunogenicity did not significantly differ between younger teens receiving two-doses and 
adolescents 15 through 26 who received three doses of the vaccine (Romanowski et al., 2016). 
The ACS also reviewed evidence provided by the CDC (2016), and their results supported 
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current CDC recommendations related to vaccinations obtained younger in adolescents (Saslow 
et al., 2016).  
Theory 
The social cognitive theory (SCT) is comprised of three types of expectancies: situation-
outcome expectancy, action-outcome expectancy, and self-efficacy expectancy (Luszczynska & 
Schwarzer, 2005). (See Appendix F for visual diagram). Situation expectancy is the belief that 
consequences will occur without an interfering personal action. Action expectancy is the belief 
that a behavior will or will not lead to a behavior. Self-efficacy expectancy is the belief that a 
behavior is or is not within an individual’s control (Luszczynska & Schwarzer, 2005).  
Research has utilized the SCT to predict reasons for HPV vaccine intent in adolescent 
women (Priest, Knowlden, & Sharma, 2015).  When deconstructing the SCT, HPV vaccination 
intent and education seamlessly coincide with one another. For example, situational-outcome 
expectancy is one’s perception of HPV. Action-outcome expectancy is the belief that obtaining 
the HPV vaccine is an effective way to prevent the HPV virus. Self-efficacy expectancy is the 
confidence an individual achieves when being an active participant in their health decision 
(Priest, Knowlden, & Sharma, 2015). Based on the SCT, studies performed by May et al., (2015) 
and Bhatta & Phillips (2014) have identified self-control and situational perception as key 
predictors of HPV vaccine uptake (Priest, Knowlden & Sharma, 2015). 
Methods 
Institutional Review Board and Site Agreement 
The primary Institutional Review Board (IRB) for this project was UMKC. This student 
investigator was in close contact with the APRN prior to and during project implementation to 
ensure project acceptance at the pediatric clinic. This study was classified as not-human subject 
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research or evidence based quality improvement (EBQI). There is a wide spectrum of activities 
involved within EBQI, with many similarities to clinical research (Melnyk & Finout-Overholt, 
2015). This intervention attempted to improve quality based on current literature (see Appendix 
G for the IRB approval letter).  
Ethical Considerations and Funding 
 Confidentiality and consent are the main ethical issues in this project to ensure participant 
protection. Confidentiality is important to adolescents when being treated in a primary care 
setting (Berlan & Bravender, 2009).  This will be managed through secure electronic databases, 
and the student investigator will not report identifying information in this project. Informed 
consent with minors is difficult in the state of Missouri (National Conference of State 
Legislatures, 2017). Currently, Missouri law allows minors access to treatment and screening of 
venereal diseases without parental consent, but explicit minor consent to receive the HPV 
vaccine is not approved at this time (National Conference of State Legislatures, 2017). For this 
project, consent for the HPV vaccine will be addressed with both the parent and adolescent. The 
student investigator did not have any conflicts of interest related to this project.  
Currently, there are multiple federal programs that can assist with the cost of the HPV 
vaccine as well as HPV vaccine education. The Vaccines for Children (VFC) Program and 
Children’s health insurance program (CHIP) assist in covering costs for ACIP recommended 
vaccines, which includes the HPV vaccine (Kaiser Foundation, 2017). Projected costs for this 
project include paper and ink cartridges totaling $39.97. The student investigator was not 
compensated for her time, but applied to the UMKC Women’s Council and Graduate Assistance 
Fund and received additional monetary support for travels funds associated with project 
dissemination at the Arkansas Nurse Practitioner Association (ANPA) Conference.  
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Setting and Participants  
This study took place in the pediatric clinic located in an urban area of Kansas City, 
Missouri. A consecutive convenience sampling method included male and female adolescents 
age 11 through 14 entering the clinic for a well-child check or sports physical. The sample size 
was ten participants. Inclusion criteria for participants require them to be between the ages of 11 
and 14 years, being seen for a well-child check or sports physical, and have not previously 
received the HPV vaccine. Individuals were excluded based on age, appointment type, and 
completion of the HPV vaccine series. 
EBP Intervention 
The intervention used an education bundle to evaluate the effect of education on vaccine 
uptake rates. Office staff provided HPV vaccine specific handouts to patients and their parents 
prior to the appointment. Providers discussed consequences related to HPV, effective prevention 
strategies, and concluded with the adolescent’s current HPV vaccine status.  
The pediatric clinic provides care to individuals beginning at infancy through 18 years of 
age. This project focused exclusively on adolescents 11 through 14 years of age. Participant 
recruitment occurred through convenience sampling of all male and female adolescents age 11 
through 14 years who entered the clinic for a well child-check or sports physical. Once the 
patient checked in for their appointment, immunization records were reviewed by office staff 
from the Missouri Department of Health and Senior Services (MDHSS) website. If he or she had 
not received the first dose of the HPV vaccine series then the individual will be eligible to 
participate in the project. The adolescent’s paperwork was subsequently flagged for the provider 
to identify an individual eligible for the education bundle.  
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During the initial stage of the intervention, the student investigator educated office staff 
and providers about clinical guidelines, current recommendations, and local immunization rates 
to gain staff cooperation.  Next, the student investigator provided the medical assistants and 
office secretaries with HPV vaccine specific educational handouts. These handouts were 
retrieved from the CDC website, and were tailored to adolescent parents addressing common 
objections raised by parents. Handouts were available in both English and Spanish to address 
diversity and literacy concerns at this clinic. The front office staff was educated on eligible 
participants, demographics, and how to review HPV vaccination status prior to the appointment. 
Individuals who had not received the first dose of the HPV vaccine were flagged to notify the 
provider of eligibility. Handouts were then provided to adolescents and their parents who met 
inclusion criteria prior to seeing the provider.  
At the adolescent appointment, the APRN discussed consequences related to HPV, 
effective prevention strategies, and concluded with the adolescent’s current HPV vaccine status. 
Once reviewing eligibility to receive the HPV vaccine, the provider asked the adolescent and 
parent if the adolescent would like to receive the HPV vaccine at this visit. If he or she consented 
to the vaccine it was administered at the appointment and immunization records were updated. If 
the participant or parent did not consent to the HPV vaccine, immunization records remained 
unchanged. Reason for refusal was not documented due to current electronic database barriers. 
Further, the student investigator evaluated if a follow-up appointment was scheduled to receive 
future vaccines in the series. A visual breakdown of this interventional flow diagram is provided 
(see Appendix H; Appendix I). 
Future additions to this education bundle can include presenting the clinic with HPV 
educational posters in the waiting rooms and exam rooms to reinforce vaccine recommendations. 
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Parents could report the main reason for vaccine consent of refusal in written documentation that 
would be provided to the clinic by the student investigator. Lastly, in order to promote uptake of 
the second dose of the HPV vaccine, parents could sign up to receive reminders such as text 
messages to obtain the second dose of the series six months following the initial appointment. 
Change Process, EBP Model 
The Change Curve Model is evident within the student investigator’s EBP project. This 
model states there are basic assumptions for change within an organization (Melnyk & Fineout-
Overholt, 2015). These assumptions state that group change requires individual change, 
leadership is necessary for fundamental change, and that change is an emotional process (Melnyk 
& Fineout-Overholt, 2015). This five-stage process stresses stagnation, preparation, 
implementation, determination, and fruition within the model (Melnyk & Fineout-Overholt, 
2015). The author has already addressed stagnation and preparation when the project was 
developed. A visual diagram of application of the project is provided (see Appendix J).  
The Model for Evidence-Based Practice Change was used in this project. This six step 
process assesses the need for change in practice, collects and analyzes the evidence, and designs 
a practice change to implement and maintain change overtime (Melnyk & Fineout-Overholt, 
2015). The student investigator has utilized this model in the development of the project by 
identifying a problem, locating and synthesizing evidence regarding HPV vaccine uptake, and 
has designed a practice change that has been implemented.  
There is a high likelihood of project sustainability once it is completed. HPV vaccination 
status can continue to be reviewed to identify eligible adolescents. The education session is brief 
and can be replicated upon project completion. The educational written materials can be utilized 
for future appointments. Handouts can be given to adolescents and their families prior to well 
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child checks, posters can be placed in waiting rooms and exam rooms, and providers can 
continue to recommend the HPV vaccine. This use of education can continue to increase 
knowledge regarding HPV and the HPV vaccine, and ultimately improve HPV vaccine uptake 
among this crucial population.  
Study Design 
 This project was implemented at an urban pediatric clinic. A quantitative quasi-
experimental single-cohort design was used. The author evaluated gender, ethnicity, age, and 
immunization status to obtain baseline variables. Next the education bundle was utilized for all 
eligible participants and concluded with evaluation for immunization uptake. Immunization 
uptake was then evaluated post-intervention. The impact of the education bundle was measured 
by HPV vaccine acceptance of the first dose or refusal of the vaccine among adolescents age 11 
through 14. Results were then compared to baseline data from retrospective chart reviews. 
Validity 
When evaluating internal validity, it is important to consider previous studies, the 
significance of the problem, the feasibility of the study, and the proposed setting (Melnyk & 
Fineout-Overholt, 2015).  Internal validity was controlled within this study by minimizing 
threats and managing extraneous variation (Polit & Beck, 2012). This study had a convenience 
consecutive sample of all adolescents age 11 through 14 being seen for a sports physical or well 
child-check which eliminates self-selection (Polit & Beck, 2012). Retrospective chart review 
selection was also conducted by convenience sampling. This study also occurred over three 
months which will reduce maturation over time (Melnyk & Finout-Overholt, 2015).  
The pediatric clinic provides care to a demographically diverse population, allowing for 
generalizability and promoting change within the community. External validity was strengthened 
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through the clearly defined educational bundle (Melnyk & Fineout-Overholt, 2015). Frameworks 
provided by the SCT and EBP model for change has guided the development of this intervention, 
and is beneficial for reproducibility in similar studies. Reproducibility and feasibility allow for 
future studies and generalizability within transferability of the intervention.   
Outcomes and Measurement Instruments 
The primary outcome was to increase initiation of the HPV vaccine among eligible 
adolescents 11 through 14 years of age who participated in the education bundle. These results 
were then compared to baseline data from retrospective chart reviews. A data collection template 
has been provided (see Appendix K). The primary outcome was measured by the incidence of 
obtaining the first dose of the HPV vaccine. Secondary outcomes related to this education bundle 
include scheduling follow up appointments for the second dose of the series if eligible. A logic 
model describing potential short and long-term outcomes represents the project (see appendix L).   
HPV immunization records were retrieved from the MDHSS once the patient checked in. 
The reliability and validity of immunization status prior to the appointment is dependent on 
whether vaccines were obtained in the state of Missouri. Validity and reliability of the HPV 
vaccine uptake rate post-intervention do not need to be evaluated since this measurement is an 
objective rate. Previous studies have reported a high level of accuracy when using the NIS-teen 
to evaluate overall HPV vaccine coverage (Dorrell, Jain, & Yankey, 2011). HPV vaccine uptake 
has the highest accuracy within the NIS-teen with a kappa level of 0.92 (Dorrell, Jain, & Yankey, 
2011). There is no procedure associated with participant completion related to this intervention, 
and permission to use the NIS-teen is not necessary because it is readily available to the public.  
Quality of Data 
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A power analysis was performed to calculate a significant sample size needed for this 
study. This was calculated with a chi-square test with a medium effect size of d=0.5, a power of 
0.8, degree of freedom of 1, and an alpha of 0.05. This provided a power analysis of 31.4 
participants in this quasi-experimental single-cohort study (ANZMTG Statistical Decision Tree, 
2018). Benchmark measurement from the NIS-teen improve quality due to the high accuracy 
(Dorrell, Jain, & Yankey, 2011). Measurements regarding pre-intervention immunization status 
improved quality of this study because it accounts for all vaccinations received in the state of 
Missouri. Measurements post-intervention are objective and improve reliability and quality.  
Previous literature has utilized HPV vaccine initiation and uptake as measured outcomes 
in similar studies (Kessels, 2012; May et al., 2017; Monfunanya, 2011). HPV vaccine uptake has 
been utilized to demonstrate the effect of both knowledge and education (McBride & Singh, 
2017; Spleen et al., 2011). The data collected can be compared to the current published data 
regarding the effect of education on HPV vaccine uptake among adolescents eligible to receive 
the 2-dose HPV vaccine series. HPV vaccine data was also compared to current benchmark HPV 
vaccination status within Missouri utilizing the NIS-teen. Potential threats to the quality of the 
data include errors in collecting data as well as missing data or incorrectly updated immunization 
status. This student investigator was the only person collecting data to prevent transcription 
errors.   
Analysis Plan 
Data collected in this quasi-experimental study were analyzed utilizing descriptive 
statistics, chi-square, and Fisher’s Exact Test. Demographics, which included age, gender, and 
race, were collected and reported. Analysis allows for interpretation of changes from pre-to-post 
intervention (see Appendix M).  
HPV VACCINE EDUCATION 
 
21 
Results 
Setting and Participants 
 This project took place at an urban pediatric primary care clinic located in Kansas City, 
Missouri from September 2018 to November 2018. This project had a goal of 31 participants, 
and obtained ten individuals in the intervention group and 16 in the retrospective group. 
Participants who participated in the education bundle ranged in ages from eleven though 14 years 
old, and ethnicities were limited to African American and Caucasian. Genders included six 
females and four males in the intervention group.  
Intervention Course 
During the month of August 2018, the student investigator performed a retrospective 
chart review of all adolescents seen at the pediatric clinic for a well child-check and were eligible 
to receive the first dose of the HPV vaccine. Sixteen adolescents were identified as eligible and 
all pertinent data from each visit were collected. An HPV vaccine in-service then occurred in 
September of 2018, and the student investigator educated staff and healthcare providers on the 
purpose of the evidence-based project. Healthcare providers were given specific information 
related to the significance of the HPV infection, local HPV vaccine rates, and current clinical 
guidelines. A second in-service took place in October 2018 to answer further questions by staff 
and address concerns related to the intervention. 
This intervention took place from September 2018 to November 2018 and recruited ten 
adolescents. Each participant and their parents during this time period were given written 
educational materials prior to the appointment and verbal education during the appointment 
addressing common concerns related to the vaccine. Each appointment concluded with 
vaccination status and participants were given the opportunity to obtain the HPV vaccine at the 
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same visit. Results were reviewed with the APRN, discussing limitations to the recruitment 
process, and the feasibility of sustaining the project in 2019. Data was then analyzed in February 
2019 with the assistance of faculty. 
Outcome Data 
 The purpose of the EBQI project was to determine whether the use of an education 
bundle improved HPV vaccine uptake among adolescents age 11 through 14 years seeking 
preventive healthcare at a local pediatric primary care clinic. Statistical analysis showed an 
improvement in HPV vaccine uptake between the intervention group and baseline group. The 
baseline group had 16 eligible individuals, where seven individuals obtained the HPV vaccine 
and nine refused. The intervention group yielded a total of ten participants where eight 
individuals obtained the HPV vaccine, and only two refused.  
 A Pearson’s Chi-square and Fisher’s exact test were performed to analyze the differences 
between the pre-education and post-education groups. The relationship between the groups did 
not yield a significant difference using either Pearson’s Chi-square test (p=.096) or Fisher’s 
Exact Test (p=.105). However, the data suggests that if the student investigator was able to 
achieve similar results with the original power analysis sample size of 31 participants, then HPV 
vaccine uptake might be significantly improved between the baseline group and intervention 
group (see Appendix N for the statistical analysis results table).  
Discussion 
Successes 
Adolescents who participated in the project were more likely to obtain the first vaccine in 
the HPV vaccine series than those who did not participate in the education bundle. When 
participants obtained the first dose of the HPV vaccine, communication with the healthcare team 
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was enhanced because individuals were given the opportunity to schedule an additional follow-
up appointment over the next six months. Education positively impacted patients by increasing 
knowledge related to the HPV vaccine and promoting overall health of the individual and 
community. A major success of this project was that HPV vaccination was increased among this 
specific population at the pediatric clinic. The project facilitator also noticed that more males 
consented to the HPV vaccine after participating in the education bundle.   
Study Strengths 
The setting was an ideal location to recruit the adolescent age group. The pediatric clinic 
serves a pediatric population from newborn to eighteen years of age. Support from the clinic staff 
was helpful as well to remind providers to offer the education bundle during the visit. This was 
done by flagging any chart where a patient was eligible to participate in the study. Staff was very 
easy to communicate and easily facilitated project implementation.  
Project implementation was initiated without barriers, and the in-service provided by the 
student investigator was helpful in obtaining support from providers. Once the project was 
initiated, clinic staff had few questions or concerns, and clearly understood the eligible 
population. Staff adequately performed all requested interventions, and stated that the project did 
not intervene with the current workflow.  
Results compared to Evidence in Literature 
 Upon analysis, the project had similar outcomes to previously published literature. Fu 
Bonhomme, and Spring (2014) focused on the audience to be educated. Results showed that 
there was a significant increase in intent to vaccinate among parents after receiving educational 
brochures, and adolescents who received CDC fact sheets report an 11% increase in vaccination 
uptake. Results from this study are similar to those of the EBQI project. Another study analyzed 
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multilingual educational materials and the effect on HPV vaccine knowledge. Results suggested 
a significant increase in knowledge among a diverse population. Both the intervention and results 
are similar to the EBQI since the student investigator utilized both English and Spanish 
educational materials, and results suggested a positive effect on HPV vaccine uptake.  
Current guidelines state that adolescents should begin the HPV vaccine series beginning 
at age 11, and should only receive two doses of the vaccine if the series is subsequently 
completed prior to age 14 (Gardner et al., 2016; Nikoyan & Fischer; Saslow et al., 2016). These 
guidelines are similar to the eligibility criteria that the student investigator utilized in this EBQI 
This project focused solely on adolescents age 11 through 14 who had yet to initiate the HPV 
vaccine series. Another similarity between the EBQI and studies performed by Spleen (2011) 
include a similar setting such as a private healthcare facility. Adolescent caregivers attended an 
HPV educational session prior to their healthcare appointment and were provided with a 
questionnaire following the appointment. When followed up in one month 100% of participants 
continued to state the education was helpful, and 44% of the caregivers reported initiating the 
vaccine series.  
While there are many similarities between this EBQI and current literature, there are a 
few important differences to highlight. Two quantitative studies focused on the use of 
questionnaires when evaluating patient knowledge related to the HPV vaccine (Bhatta, & 
Phillips, 2014; Tung, Machalek & Garland, 2016). Questionnaires revealed that education 
provided an increase in HPV-related knowledge however, results did not provide further 
correlation to overall initiation of the HPV vaccine.  
Limitations 
Internal and External Validity  
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There were several limitations that were identified within this EBQI. When discussing 
internal validity, it is important to highlight that this project implemented a consecutive 
convenience sample for both the baseline and intervention group. While this technique was 
beneficial to obtaining participants, the overall sample size was still relatively small and did not 
produce significant results. The project also occurred over a three-month time frame which 
assisted in reducing maturation over time (Melnyk & Fineout-Overholt, 2015). However, 
between the months of September and November the number of preventive visits were relatively 
low compared to other months. 
External validity was strengthened through the framework which guided this EBQI. The 
EBQI utilized the SCT and EBP Model for Change which is beneficial for future reproducibility. 
However, due to the small sample size and lack of diversity among the participants, results did 
not allow for generalizability. Another confounding variable is the lack of a standardized 
education process. While the student investigator provided the clinic with a clearly defined 
education bundle which consisted of written materials and verbal education, it is difficult to 
identify that this exact process was followed with every participant. Another limitation that was 
identified in this project was that many of the eligible population had already received the first 
dose of the vaccine and were not eligible for this project.  
Sustainability of Effects and Plans to Maintain 
 A common problem found was that the eligible age group was either being seen for an 
acute visit or had already initiated the HPV vaccine series. Current literature and study results 
show that education has a positive impact on overall HPV vaccine acceptance (Spleen, 2011). By 
addressing immunization status at not only physicals but at acute visits when deemed 
appropriate, providers can continue to promote the uptake of the HPV vaccine. It is also 
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important to note that providers can also address if the adolescent is eligible to receive the 
second dose of the series at any health visit. This will promote the overall uptake of the entire 
HPV vaccine series. Other ideas for sustainability discussed with the project facilitator include 
placing HPV vaccine brochures in the waiting rooms and HPV vaccine posters in the exam 
rooms.  
Efforts to Minimize Study Limitations 
 The student investigator attempted to minimize limitations during implementation of this 
project. Several in-services were performed during project implementation to address questions 
from staff and providers and ensure consistent use of the education bundle. If the education 
method was not consistent among participants, this could lead to different rates of uptake and 
overall skewed results. Another limitation of the project was the specific time frame of project 
implementation. The student investigator implemented this project over a three month time 
frame to reduce maturation over time and increase the number of eligible participants. However, 
upon completion of data collection and project analysis, it was noted that during the fall months 
adolescent preventive visits are relatively low. After discussing these findings with the project 
facilitator, preventive adolescent health visits are historically more common during summer 
months due to children being out of school. Lastly, the student investigator utilized a consecutive 
convenience sample to recruit participants in order to allow for greater generalizability. This was 
limited by uneven distribution among gender, age, and ethnicity.  
Interpretation 
Expected and Actual Outcomes 
Participants were expected to receive the first dose of the HPV vaccine series upon 
completion of the education bundle. The student investigator provided several in-services 
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throughout the project to ensure consistent usage of the education bundle. While overall HPV 
vaccine uptake was higher among the intervention group compared to the baseline group, there 
were several problems that arose during implementation. 
            The student investigator encountered several difficulties during project implementation. 
First, participant recruitment was much lower than expected. The student investigator expected 
to recruit a minimum of 30 participants over the three-month time period, but was only able to 
recruit 10. Many of the eligible age group had already started the HPV vaccine series and were 
ineligible for this particular project. This small sample size did not prove significant results upon 
further analysis. One additional failure identified was that the student investigator was unable to 
evaluate if a participant made a future appointment for the second dose of the vaccine series due 
to electronic medical record complications 
Intervention Effectiveness and Revisions 
This project would continue to be most effective in a pediatric or adolescent primary care 
facility. Children and adolescents account for 18% of preventive care visits, so this would be the 
most effective setting for further participant recruitment. Additional project modification would 
include acute care visits in the criteria when providing the HPV vaccine education bundle. Since 
many eligible adolescents were not being seen for preventive visits, acute visits would still 
provide a private setting to implement the project and increase recruitment. 
The education bundle positively impacted patients and their families because it increased 
overall knowledge and increased HPV vaccine uptake. The intervention could also widen its 
criteria to include overall completion of the HPV vaccine series.  This project is a cost-effective 
intervention that could be seamlessly continued within the clinic upon project completion. 
Expected and Actual Impact 
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 The estimated cost of the EBQI project, with the exception of dissemination costs, was 
$39. These costs consist of paper and ink in order to print the HPV vaccine educational 
materials. The student investigator was not compensated for her time during project 
implementation, analysis, and dissemination. Estimated dissemination costs were $860.00. 
Actual dissemination costs were $767.45. Dissemination costs included poster creation, airfare 
and lodging in Little Rock, Arkansas, and conference fees. This EBQI has additional funding 
from the UMKC Women’s Council Graduate Assistance Fund. The student investigator received 
the Patricia Brous Award and was granted $400 for project dissemination and associated travel 
costs.  
 This EBQI has a high likelihood of sustainability upon project completion. This project 
has minimal associated costs and would be easy to integrate into the practice. This intervention 
can be easily maintained, and the only additional costs would be paper and toner for the written 
materials. Additionally, educational material can be printed in black and white in order to further 
decrease any costs.  
Conclusion 
HPV is a serious problem in the United States contributing to increased STIs and cervical 
cancers (CDC, 2015; Romanowski, 2016). It is important that adolescents be aware of these 
serious health risks and make informed decisions regarding their healthcare. Education is a 
simple intervention that healthcare providers can offer to increase knowledge and change 
previous attitudes regarding the virus (Cox, 2010; Rhodes et al., 2017; Tung et al., 2016). 
 Current literature shows that educating adolescents about HPV has raised overall 
awareness of HPV and cervical cancer, changed parental attitudes toward the HPV vaccine in a 
positive way, and ultimately increased HPV vaccination uptake among adolescents (Bhatta & 
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Phillips, 2014; Cox, 2010; Fu et al., 2014; Spleen, 2011; Tung et al., 2016). When adolescents 
consistently accept the HPV vaccine, the overall prevalence and transmission of HPV are 
decreased, and up to 33,000 cases of cervical cancer can be prevented annually in the United 
States (CDC, 2015; Printz, 2015). Future studies can evaluate the effect of education in relation 
to increased knowledge, improved intent to vaccinate, improve uptake of the second dose of the 
HPV vaccine, and specific demographics. Researchers can further evaluate the effect of parental 
presence at the appointment and which specific parent was present in relation to HPV vaccine 
intent and uptake. Project results will be presented at the Arkansas Nurse Practitioner 
Association conference on April 12, 2019. 
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Appendix A: HPV Education
 
 Retrieved from: https://www.cdc.gov/vaccines/parents/diseases/teen/hpv-basics-color.pdf 
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Appendix B: Cost Table 
CDC STD prevention and 
education Funding 
  
Projected start date: 
9/1/18 
  
Item Costs Notes 
Salary Kristina Collins- 
DNP graduate Student 
$0.00 Student will not be 
compensated for data 
collection 
RN hourly rate $35.00/hour uncompensated 
Educational materials $6.03/550 pieces of paper 
$33.94/ 2 black ink cartridges 
Additional printers if 
needed 
Possible colored handouts 
would increase ink costs 
Total project costs $39.97  
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Appendix C: Definition of Terms 
• Consent: permission for something to happen, or an agreement to do something (CDC, 
2016) 
• Education bundle: an evidence based, structured set of HPV specific educational 
interventions used for adolescents age 11-14 and their parents in order to improve HPV 
vaccine uptake 
• Evidence based project: incorporates evidence based quality improvement guidelines 
focused on improving HPV vaccine uptake among adolescents age 11-14  
• Human papillomavirus: a group of viruses that is spread through sexual contact that can 
lead to genital warts and certain types of cancer (CDC, 2015) 
• Vaccine uptake: the action of receiving an immunization (Dube et al., 2013) 
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Appendix D: Evidence Table 
Table of Evidence 
  
PICOTS   
In adolescent patients, age 11-14, does the use of written education materials compared to patients who received no educational 
materials increase the uptake of the HPV vaccine during a 3-month time frame in a primary care setting? 
First author, year, title, 
Journal 
Research Design & 
Evidence Level 
Sample & Sampling Measures & Reliability (if 
reported) 
Results & Analysis Used Limitations 
Subtopic: 
HPV vaccine uptake 
     
May, R., Dela Cruz, I., 
Tsark, J., Chen, J., 
Abright C., Braun, K. 
(2017) 
 
Human papillomavirus 
(HPV) vaccination 
motivators, barriers, and 
brochure preference 
among parents in 
multicultural Hawaii: A 
qualitative study  
 
Journal of Cancer 
Education   
Qualitative  
 
Level: 6, single 
qualitative study  
20 parents with a child 
11-18 years old. Data 
were collected from 
parents through face-to-
face interviews or 
telephone interviews 
10/13-1/14.  
 
Parents were recruited 
using snowball sampling 
starting with 
friends/family of 
principal investigator 
Vaccination history, HPV 
knowledge and status, 
physician recommendation, 
motivators, and intent to 
vaccinate.  
 
Reliability not reported.  
This study confirmed that a 
physician plays a critical 
role in HPV vaccination 
uptake. 70% of mothers 
stated they had learned 
about the HPV vaccine 
from their physician 
 
 
Interviews were digitally 
recorded and coded by a 
team of researchers who 
were trained in content 
analysis in order to quantify 
qualitative data.  
Sample included only 20 
parents 
 
Participants were all 
mothers or a female 
caregiver.  
Tung, I., Machalek, D., 
Garland, S. (2016). 
 
Attitudes, knowledge and 
factors associated with 
human papillomavirus 
(HPV) vaccine uptake in 
adolescent girls and young 
women in Victoria, 
Australia 
 
PloS one 
 
 
Quantitative: 
Retrospective study 
Level 3 
 
 
September 2011-
December 2014 women 
aged 18-25 living in 
Victoria Australia 
 
Targeted advertisements 
placed on social media 
website facebook 
 
 
Responses to two web-
based surveys including the 
VACCINE study survey 
were collected. Attitudes 
were assessed using seven 
point Likert scales 
 
 
Attitudes towards health, 
HPV infection and 
vaccination may impact on 
the success of the HPV 
vaccination program. 
 
Univariate and logistic 
regression analysis were 
performed with ORs and 
95% CI, p<0.100 
 
 
May be subject to bias 
recall, views of the parents 
were reported by the 
participants rather than the 
parents themselves and may 
be inaccurate 
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Bhatta, M., & Phillips, L. 
(2014) 
Human papillomavirus 
vaccine awareness, 
uptake, and parental and 
health care provider 
communication among 
11-18 year old adolescents 
in a rural Appalachian 
Ohio county in the United 
States.  
 
Journal of Rural Health 
Quantitative: 
experimental  
 
Level 3: Quasi-
experimental  
1,299 male and female 
participants 11-18 years 
old  
 
Surveys were school-
based, anonymous, and 
voluntary 
 
 
five questions regarding the 
HPV vaccine were added to 
the 2012 youth risk 
behavior surveillance 
system (YRBSS).  
 
 
95% CI 
 
Adolescents receiving any 
dose of the vaccine were 
significantly more likely to 
have had a parents or 
healthcare provider discuss 
the vaccine than those who 
did not receive any dose.  
 
Chi-square test; data 
analysis was performed 
using SAS 9.3.1 
 
Questionnaire is completely 
voluntary, and are self-
reported.  
 
Only conducted in 1 county 
I Appalachian Ohio 
 
Study did not include a 
question on intention to get 
vaccinated.  
Kessels, S. (2012). 
Factors associated with 
HPV uptake in teenage 
girls: A systematic review  
 
Vaccine 
 
Systematic Review: 
Level 3 
 Sample: 25 studies were 
analyzed during this 
study. Samples ranged 
from 52-384,869 
 
Of the 25 studies, 23 
focused on factors that 
influenced initiation of 
the vaccination program 
and 2 studies reported 
factors associated with 
the completion of the 
HPV vaccine 
 
 success was measured by 
either vaccine initiation 
and/or completion, through 
a systematic review of peer-
reviewed literature 
 
Reliability not reported.  
 
 Important factors that 
influenced initiation and 
completion of the HPV 
vaccine included race, age, 
parental and adolescent 
knowledge, and applying 
this education in schools 
would be beneficial. 
 
data was narratively 
synthesized and tabulated 
by outcome separately for 
studies reporting vaccine 
initiation and completion   
 
 Studies that were 
reviewed were not 
generalizable to the public, 
many studies did not have 
consistency, uptake rates 
that were reported were low 
when the vaccine was 
initially implemented 
nationwide, and non-
English were excluded as 
well.   
Patel, J (2012).  
 
Human papillomavirus 
vaccine intent and uptake 
among female college 
students 
 
American College of 
Health 
Quantitative: 
Randomized Control 
Trial 
 
Level 2: RCT 
256 female college 
students age 18-26 
 
Gynecology clinic at 
University of Michigan  
Participants given fact sheet 
about HPV and vaccination 
given and contents 
reviewed with study 
coordinator.  
 
P<0.05 
Baseline 41% level to 
intent, perceived parental 
approval regarding HPV 
vaccine, but overall HPV 
vaccine uptake 5.5% 
 
Chi-square t-test  
 
 
Study performed 2007-
2009  
 
Focused on female seeking 
routine healthcare  
Mofunanya, C. (2011).  
 
Improving compliance 
rate of human 
papillomavirus (HPV) 
vaccine usage among 
Quantitative, 
experimental. 
  
Level 3: quasi 
experimental 
20 patients  in an primary 
care clinic who accepted 
counseling 
  
After all patients were 
counseled, rates were 
Percentages were looked at 
who received the first 
vaccine, of those who 
received the vaccine were 
reminded of follow up 
vaccines. 
  
After counseling, 85% of 
patients accepted first dose 
of HPV vaccine. 75% 
received the second dose 
and 65% received third 
dose, exceeding national 
Small sample size not 
representative of entire 
population. 
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41 
female adolescents aged 
11 to 21 years. 
  
Doctoral dissertation 
research  
looked at who received 
the vaccine. 
  
  
  
  
Reliability not reported average compliance rate of 
27%. 
  
Comparison with national 
averages 
Subtopic: 
Education 
     
McBride, K., Singh, S. 
(2017) 
 
Predictors of Adults’ 
Knowledge and 
Awareness of HPV, HPV-
Associated Cancers, and 
the HPV Vaccine: 
Implications for Health 
Education 
 
Health Education and 
behavior 
Quantitative: Cross 
sectional approach  
 
Level: 3, quasi 
experimental 
Cross sectional survey 
data from U.S adults 
(N=3,103) were obtained 
from the HINTS 
questionnaire  
 
Sample obtained through 
a two-stage, stratified 
process where addresses 
were randomly selected 
from USPS and 
respondents were 
selected from each 
household sampled.  
HPV, HPV-associated 
cancer, and HPV vaccine 
awareness and knowledge 
items from HINTS were 
analyzed  
 
P=0.013 
 Patient–provider 
communication that 
includes education, 
counseling, and clear 
recommendations favoring 
vaccination may improve 
uptake. 
 
STATA-SE, version 13.1 
statistical analysis  
 
Data was collected via self-
report.  
 
Large percentage of the 
sample were over the age of 
50 and/or reported no 
children living in the home.  
Valdez, A. (2015).  
 
Design and efficacy of a 
multilingual, 
multicultural, HPV 
vaccine education 
intervention. 
  
Journal of communication 
in healthcare 
Quantitative, 
experimental 
  
Level 2: 
 
randomized control 
trial 
 
708 Latino and Korean 
American Parents 
  
Participants watched an 
HPV educational DVD 
and a RCT was 
conducted to assess 
knowledge gains and 
decisional conflict 
Knowledge was tested 
using a 12 T/F question 
questionnaire assessing 
knowledge gains, and 
decisional attributes 
  
P<0.05 
Findings suggest that a 
multicultural, multilingual 
intervention designed to 
educate diverse parents 
enables them to make an 
informed decision 
regarding their children and 
the HPV vaccine 
  
Treatment and control 
groups were compared 
using chi square test for 
categorical variables and t-
test for numerical variables. 
Self-selection was a major 
limitation in this study 
along with focusing on 
Latino and Korean parents 
whose views may not 
reflect the views of those of 
parents from other racial 
groups, so these findings 
may not be generalized to  a 
larger population. 
Fu, L., Bonhomme, L., 
Spring, C. (2014) 
 
Educational interventions 
to increase HPV 
vaccination acceptance: A 
systematic review  
 
Quantitative: 
Systematic Review 
 
Level 2: Systematic 
review  
 
Identified 33 studies of 
HPV vaccination 
educational interventions 
among adolescents and 
adults 
 
Searched databases of 
pubmed, web of Science 
Relating interventions with 
HPV vaccination uptake or 
intent on HPV vaccination  
 
Reliability not reported 
Finding effective HPV 
vaccination educational 
interventions is essential to 
reducing HPV-associated 
morbidity 
 
Meta-analysis 
Search was restricted to 
English-language 
publications, so results 
were bias to western 
European, Australia, and 
north America 
HPV VACCINE EDUCATION 
 
42 
Vaccine for English-language 
describing HPV 
education 
Krawczyk, J. (2012) 
 
How to inform: comparing 
written and video 
education interventions to 
increase human 
papillomavirus knowledge 
and vaccination intentions 
in young adults  
 
American College of 
Health 
Quantitative: 
randomized control 
trial  
 
Level 2: RCT 
200 male and female 
students  
 
McGill University, 
Montreal 
HPV vaccination intent on 
a 7-point scale assessed 
immediately post-
intervention  
 
Reliability not reported  
 
 
Low baseline knowledge 
and intentions were found 
across groups. Post-
intervention has higher 
knowledge and intent than 
the control, no difference 
found between written and 
video interventions  
 
 
Average age was 18 
 
Only 60 males were 
assessed in the study 
Reiter, P. (2011).  
 
HPV and HPV vaccine 
education intervention: 
effects on parents, 
healthcare staff, and 
school staff. 
  
 
Cancer epidemiology, 
biomarkers, and 
prevention  
Quantitative, 
experimental 
  
Level 3: quasi-
experimental 
376 parents, 118 health 
care staff, 456 school 
staff 
(total n = 950) 
  
All attended one 
educational session and 
completely one self-
survey 
Participants were asked 
about their knowledge of 
HPV vaccine on a scale of 
1-10, and about current 
statistics regarding HPV 
with multiple choice and 
T/F questions 
  
P<0.001 
Participants has low 
baseline knowledge 
regarding HPV, following 
education more than 90% 
of school staff believed 
HPV education is valuable 
within schools. 97% of 
parents agree and 85% of 
school staff members are 
supportive of vaccine 
clinics. 
  
Knowledge was compared 
with pre and post self-
reported surveys. Using 
SAS version 9.2 using two 
tailed statistic test 
Conducting educational 
sessions among 
convenience samples in 
only 1 county in North 
Carolina, having few male 
participants, and not having 
physicians as part of the 
sample health care staff. 
Spleen, A. (2011). 
 
 An increase in HPV-
related knowledge and 
vaccination intent among 
parental and non-parental 
caregivers of adolescent 
girls, age 9-17 years, in 
Appalachian 
Pennsylvania. 
  
Quantitative, 
experimental. 
  
Level 3: quasi-
experimental 
117 attendees of an HPV 
educational session 
  
Surveys were given prior 
to session and 
immediately following 
with a 1 month follow up 
phone interview as well. 
Pre and post-tests following 
HPV educational session 
measuring knowledge 
regarding HPV 
vaccinations 
  
p<0.05 
Knowledge summary 
scores regarding HPV 
increased from 12.9 to 14.9. 
70% reported the vaccine 
might increase promiscuity, 
49% believed their 
daughter was not at risk for 
HPV, and however, there 
was increase intent to 
vaccinate. 
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Journal of Cancer 
Education  
Two sided t-test, and 
knowledge was 
significantly increased with 
intent to vaccinate within 6 
months. 
  
Cox, D. (2010). 
Behavioral interventions 
to increase HPV 
vaccination acceptability 
among mothers of young 
girls. 
  
Health psychology  
Quantitative, 
experimental. 
  
Level 3: quasi-
experimental 
522 mothers of daughters 
aged 11-16. 
  
Recruited from an online 
national survey 
purchased from SSI 
Mothers were directed to 
the survey and were given 
education and asked if they 
would vaccinate their 
daughters. 
  
P< 0.05 
Both risk intervention 
formats appear to be 
effective when used 
separate than when used 
together and increase 
vaccine acceptability. 
  
One-way ANOVA 
statistical analysis 
  
Variables included parents, 
not adolescents. 
  
Intervention was not used 
in a clinical setting 
  
The study should be 
implemented in a 
randomized control study. 
Wetzel, C., Tissot, A., 
Kollar, L., Hillard, P., 
Stone, R., Kahn, J. (2007) 
 
Development of an HPV 
educational protocol for 
adolescents  
 
Journal of pediatric and 
adolescent health  
Quantitative, 
experimental.  
 
Level 3: quasi-
experimental  
252 adolescent girls and 
boys in the three study 
phases 
Phase 1: investigators 
developed the protocol. 
Phase 2: adolescents 
evaluated the protocol 
qualitatively, investigators 
evaluated its effectiveness 
in increased HPV 
knowledge. Phase 3: 
investigators evaluated the 
effectiveness of the revised 
protocol 
 
P<0.0001 
Scores on the HPV 
knowledge scale increased 
significantly among 
adolescents who 
participated in phases 2 and 
3 after they received the 
protocol  
Limitations: small sample, 
multiple phases within 1 
study leading to an increase 
in variables.  
Subtopic: 
Clinical Guidelines 
     
American College of 
Obstetrics and 
Gynecology (ACOG) 
(2017). Human 
papillomavirus 
vaccination.  
 
Evidence based 
guideline -level 1 
 
 
Recommendations and 
conclusions regarding the 
human papillomavirus. 
Adolescents 9-26.  
 
 
For girls and boys who 
receive their first dose of 
HPV vaccine before 15 
years of age, only two 
doses are needed. The 
timing of the two doses is 0 
(baseline) and 6–12 
months. If the interval 
between the two doses is 
less than 5 months, a third 
dose is recommended. If 
females or males receive 
their first dose at 15 years 
Obstetrician–gynecologists 
and other health care 
providers should stress to 
parents and patients the 
benefits and safety of HPV 
vaccination and offer HPV 
vaccines in their office  
 
 
No limitations identified 
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of age or older, three doses 
are needed and given at 0 
(baseline), 1–2 months after 
the first dose, and 6 months 
after the first dose. 
 
 
Saslow, D., Andrews, K. 
S., Manassaram‐Baptiste, 
D. (2016) 
 
Human papillomavirus 
vaccination guideline 
update: American Cancer 
Society guideline 
endorsement  
 
A cancer journal for 
clinicians  
Evidence based 
guideline-level 1 
 
 
The CDC conducted a 
content review of the 
ACIP HPV vaccine use 
recommendations as part 
of the ACS endorsement 
process. The objective of 
the content review was to 
assess the specific 
recommendations made 
and the extent to which 
the available evidence 
supports each 
recommendation  
 
 
 
The American Cancer 
Society (ACS) reviewed 
and updated its guideline on 
human papillomavirus 
(HPV) vaccination based 
on a methodologic and 
content review of the 
Advisory Committee on 
Immunization Practices 
(ACIP) HPV vaccination 
recommendations  
The ACS recommends 
vaccination of all children 
at ages 11 and 12 years to 
protect against HPV 
infections that lead to 
several cancers and pre-
cancers.  
 
 
No limitations identified  
Garland, S., Kjaer, S., 
Munoz, N., Block, S. 
(2016) 
 
Impact and effectiveness 
of the quadrivalent human 
papillomavirus vaccine: a 
systematic review of 10 
years of real-world 
experience 
 
Clinical infectious 
diseases 
 
Quantitative: 
Systematic review-
level 2 
 
 
Searching pubmed for 
903 articles, 58 
publications with 
observational studies of 
effectiveness of HPV 
vaccination on HPV 
infectious disease were 
considered 
 
 
HPV vaccine uptake 
compared with HPV 
infection active of 
6/11/16/18 over 10 years to 
determine efficacy 
 
 
Subsequent to introduction 
of the HPV vaccine, 
consistent decreases in 
prevalence of HPV 
6/11/16/18 among females 
in their teens and 20s 
 
 
Assessment of population 
impact depends on multiple 
factors including the 
breadth of the 
immunization program, 
completeness and accuracy 
of data sources, availability 
and utilization of screening 
programs,. 
 
 
Nikoyan, E., Fischer, P. 
(2016) 
 
CDC recommends simpler 
HPV vaccine series for 
young adolescents 
 
Infectious disease alert 
Evidence Based 
guideline- level 1 
 
 
CDC and the Advisory 
Committee on 
Immunization Practices 
(ACIP) made this 
recommendation after a 
thorough review of 
studies indicating that 
two doses of HPV 
Evidence-based approach to 
recommend treatment 
change in HPV dosing in 
younger adolescents. 
 
 
The recommendation for a 
two-dose HPV vaccination 
schedule for younger 
adolescents should lead to 
higher completion rates 
than those achieved with 
the three-dose HPV 
There are still major 
barriers that exist to 
reaching the goal to 
increase HPV vaccination 
coverage of males and 
females. 
 
 
HPV VACCINE EDUCATION 
 
45 
 vaccine in 9- to 14-year-
olds produce an immune 
response similar to or 
greater than the response 
in young adults older 
than 15 years of age who 
received three doses. 
 
 
vaccination schedule in the 
United States. 
 
 
 Workowski, K. (2010) 
Human 
papillomavirus (HPV) 
infection. In: Sexually 
transmitted diseases 
treatment guidelines. 
Centers for disease control 
and prevention 
 
 Evidence based 
practice guideline.  
Systematic review 
with evidence tables: 
Level 1 
 
 Searches of electronic 
databases.  
 
Number of sources not 
specified. 
 
 the CDC used expert 
consensus to formulate the 
major recommendations 
validated by peer review 
 
 
 
 
 Women older than 30 
undergoing cervical cancer 
screening should be tested 
for HPV, treat individuals 
with lesions and symptoms 
with antivirals but do not 
treat those with sub-
clinical HPV due to 
overexposure to antivirals. 
and lastly vaccinate all girls 
aged 13-26 and males aged 
9-26 to prevent against 
HPV and genital warts.  
 the CDC reviewed 
published meta-analysis 
and systematic review with 
evidence tables 
 
No limitations identified  
Running head: HPV VACCINE EDUCATION  46 
 
 
Appendix E: Hierarchy of Evidence 
Rating System for the Hierarchy of Evidence 
For an Interventional Inquiry 
(Modification by Dr. Lindholm for course N5613) 
Level  I  
Evidence from a systematic review or meta-analysis of all relevant 
RCTs.  Evidence-based clinical practice guidelines based on 
systematic reviews of RCTs).*                                                                                             
Level  II  
Evidence obtained from well-designed RCT.                                               
Quantitative systematic review of well-designed controlled trial 
without randomization. 
Level  III  
Evidence obtained from well-designed controlled trial without 
randomization (quasi-experimental).                                                           
Quantitative systematic review of case-control, cohort, or 
correlational studies.                                                           
Level  IV 
Evidence from well-designed case-control or cohort study  (or 
cross-sectional study)  
Level  V  
Evidence from systematic review of quantitative descriptive (no 
relationships to examine) or qualitative studies. 
Level  VI  
Evidence from a single quantitative descriptive (no relationships to 
examine in the study) or qualitative study  
Level  VII  
Evidence from the opinion of authorities and/or reports of expert 
committees 
 
 
 
 
 
 
 
Melnyk, B.M.& Fineout‐Overholt., E. (2015). Evidence-based practice in nursing and 
healthcare. Philadelphia Lippincott Williams & Wilkins,.  
*Italics, appropriate in this category, modification by LL 2017 based on opinions from 
experts to place SR at one level higher than single study design level.  
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Appendix F: Social Cognitive Theory 
 
 
Reinforcement:   Outcome Expectations:  Self-Observation 
Perceived consequences  Outcome Expectancies:  Self-Judgement 
Various reinforcement   Efficacy Expectations:  Self-Reaction 
Self-reinforcement   performance Accomplishments 
Observational Learning:  vicarious experiences 
Attentional processes   verbal persuasion 
Retention processes   physiological State 
Motor reproductive processes 
Acquisition processes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Retrieved from: 
http://www.ntcu.edu.tw/je0071/Health%20Promotion%20Planning%20Indina/p4p1.htm 
HPV Vaccine Acceptance
Environment: 
Concerns the vaccine will 
increase promiscuity
Personal: 
The HPV vaccine will 
decrease cervical cancer 
risk
Behavior: 
Recieving the HPV vaccine 
empowers individuals 
regarding health deicisions
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Appendix G: IRB Approval Letter  
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Appendix H: Intervention flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Step 1: Perform 3-month 
retrospective chart review in 
fall of 2017 
(Student Investigator) 
Step 2: Is child being seen for 
a well child check or sports 
physical? 
(Front Office Staff)  
Step 4: Provide participant 
with written HPV vaccine 
specific educational handout 
 
(Front Office Staff) 
Step 5: Provide adolescent 
and parent with education 
related to HPV and the HPV 
vaccine 
(Healthcare provider) 
Step 6: Ask adolescent and 
parent if he or she would like 
to obtain the first HPV 
vaccination at this visit (yes or 
no) 
(Healthcare provider) 
 
Y 
Y 
Step 3: Is adolescent 
between ages of 11-
14 and not received 
the HPV vaccine? 
 
(Front Office Staff) 
Not eligible 
for project  
 
Not eligible 
for project  
N 
N 
Step 7: Evaluate HPV vaccine 
uptake after education bundle 
in comparison to retrospective 
chart review rates 
(Student Investigator) 
 
Step 8: Compare HPV 
vaccine uptake to 
benchmark data obtained 
from NIS-teen 
(Student Investigator) 
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Appendix I: Timeline Flow Chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spring 2018
• Identify 
problem
• Develop 
evidence 
based 
intervention
• Identify 
setting and 
engage 
project 
facilitator
Fall 2018
• Finalize 
bundle
• Educate office 
staff and 
providers at 
SHS regarding 
problem and 
local issue
• provide 
materials and 
implement 
education 
bundle
Spring 2019
• Collect 
pertinent data 
provided in 
fall of 2018
• data analysis
• Dissemination 
of findings
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Appendix J: Change Curve Model Diagram 
  
Melnyk, D.M. & Fineout-Overholt, E. (2015). Evidence-based practice in nursing 
and healthcare: a guide to best practice (3rd ed). Philadelphia: Wolters 
Kluwer/Lippincott Williams & Wilkins. 
Step 1
• Stagnation: In Missouri only 38 percent of girls and 
33 percent of boys have received and completed the 
HPV vaccine series (CDC, 2015).  
Step 2
• Preparation: Collect HPV-vaccine specific written 
education materials and identify potential funding 
opportunities and setting for the intervention
Step 3
• Implementation: implement utilization of 
educational bundle for 3 months 
Step 4
• Determination: Evaluate HPV vaccine uptake rates 
among eligible participants to results from previous 
baseline chart review
Step 5
• Fruition: Continue to implement education bundle 
at Swope Health Services after completion of EBP 
project 
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Appendix K: Data Collection Template 
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Appendix L: Logic Model 
Rev. 7/09, 1/2015   http://www.uwex.edu/ces/lmcourse/interface/coop_M1_Overview.htm  Logic-Model Worksheet 
content revisions by Lyla Lindholm for DNP Project. Not to be placed on web for public use. For UMKC DNP 
coursework only.  
 
Logic Model for DNP Project   
Student: Kristina Collins 
Inquiry, PICOTS: (P) In adolescent patients, age 11-14, (I) does the use of and education 
bundle (C) compared to patients who received no educational materials (O) increase the 
uptake of the HPV vaccine (T) during a 3-month time frame (S) in a primary care 
setting? 
Inputs 
 Intervention(s)                        
Outputs 
 Outcomes -- Impact 
 Activities Participation  Short Medium Long 
Evidence, sub-
topics 
1.HPV vaccine 
uptake 
2. HPV vaccine 
education 
3. Clinical 
guidelines 
 
Major 
Facilitators or 
Contributors 
1. High level of 
knowledge 
regarding HPV 
2. Provider 
recommendation 
3. clinical 
guideline 
recommendations 
4. efficacy of the 
vaccine 
 
Major Barriers 
or Challenges 
1. low-level of 
knowledge 
regarding HPV 
2. perceived 
attitudes of the 
vaccine 
3. access to 
healthcare 
4. cost and safety 
of the vaccine 
 EBP 
intervention 
which is 
supported by 
the evidence 
in the Input 
column (brief 
phrase)  
Provide HPV-
specific 
education and 
educational 
materials to 
adolescents 
age 11-14 
Major steps of 
the 
intervention 
(brief phrases) 
1. obtain 
Jackson county 
HPV vaccine 
rate 
2. Screen for 
eligibility 
3. Provide 
education 
bundle to 
eligible 
adolescents 
4. Receive/ 
refuse first dose 
of HPV vaccine 
5. Evaluate 
HPV vaccine 
uptake rate 
between 
intervention 
group and chart 
review 
The 
participants 
(subjects)   
All 
adolescents 
age 11-14 
entering SHS 
being seen 
for a WCC or 
sports 
physical, not 
yet received 
the HPV 
vaccine 
Site 
SHS-pediatric 
clinic 
Time Frame  
3 months 
Consent or 
assent 
Needed  
Consent 
needed to 
receive 
vaccination 
 
Other 
person(s) 
collecting 
data  
No 
Others 
directly 
involved in 
consent or 
data 
collection  
yes 
 (Completed 
during DNP 
Project)  
Outcome(s) 
to be 
measured 
Primary: 
increase in 
HPV vaccine 
uptake among 
adolescents 
after receiving 
education 
bundle 
compared 
previous chart 
review with no 
bundle 
 
Measurement 
tool(s) 
1. HPV 
vaccine 
uptake rate 
 
Statistical 
analysis to 
be used 
1. chi-square 
test 
(after 
student 
DNP)  
Outcomes to 
be measured  
The author 
will measure 
the HPV 
vaccine 
uptake rate 
among 
eligible 
adolescents 
in pre-and 
post 
education. 
HPV vaccine 
uptake rates 
will be 
compared 
between both 
groups to 
evaluate the 
effectiveness 
of education. 
If uptake is 
increased 
among the 
intervention 
group, the 
intervention 
will be 
considered a 
success. 
(after 
student 
DNP) 
Outcomes 
that are 
potentials  
1. improve 
HPV vaccine 
intent, 
without 
actual uptake 
2. increase 
knowledge 
related to 
HPV, but not 
improve HPV 
vaccine 
uptake 
 
3. change 
attitudes in a 
positive way 
regarding the 
HPV vaccine, 
but not 
improve HPV 
vaccine 
uptake 
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Appendix M: Statistical Analysis Template Table 
 Intervention Group Baseline Group Significance (p) 
Participants    
Mean Age    
Gender    
Race    
HPV Vaccine 
Uptake 
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Appendix N: Statistical Results Table, Vaccination Pre and Post 
 Value df Asymptomatic 
Significance 
 (2-sided) 
Exact 
Significance 
(2-sided) 
Exact 
Significance 
(1-sided) 
Pearson Chi-
Square 
2.778 1 .096   
Fisher’s 
Exact Test 
   .211 .105 
 
